Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

luded and various authorizations are secured.
  • Spain – Considering a Royal Decree introduced in 2012 affecting health care expenditures and pharmaceuticals, and the continuing economic challenges of the country, forecasting of the timing of pricing and reimbursement decisions has become more challenging for all manufacturers.  As a result, InterMune currently believes that it is more likely that a decision regarding pricing and reimbursement of Esbriet in Spain will occur in the first half of 2013 than in the fourth quarter of this year.
  • The UK – InterMune today confirmed its previous guidance that the appraisal by the National Institute for Health and Clinical Excellence (NICE) is expected to be completed in March of 2013.  If NICE provides a positive appraisal for Esbriet, the company expects to launch Esbriet as soon as possible thereafter.
  • Mid-Sized Countries (MSC) – In addition to the seven MSC for which Esbriet pricing has been secured, the company expects to conclude pricing and reimbursement processes in the remaining three MSC of Netherlands, Finland and Ireland in the first half of 2013 and launch as soon as possible thereafter, assuming that acceptable pricing and reimbursement conditions are negotiated in these countries.
  • InterMune confirmed its earlier guidance that it expects to have launched Esbriet in all top 5 markets and 10 mid-sized markets in Europe, comprising 75 percent of the EU population and 80-85 percent of the European pharmaceutical market, in the second quarter of 2013, assuming acceptable pricing and reimbursement is secured. 
  • Enrollment of InterMune's Phase 3 pirfenidone study, ASCEND, in the United States and certain additional territories continues to proceed according to plans.  The company expects the study to be fully enrolled around the end of 2012, and that results from the study will be available in the first half of 2014.  AS
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune To Release Third Quarter Financial Results On November 7
    2. InterMune To Present At JMP Securities Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune to Present at J. P. Morgan Healthcare Conference
    5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
    8. Patient Safety Technologies Reports Third Quarter 2012 Results
    9. PDI Reports 2012 Third Quarter Financial Results
    10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    11. Neurocrine Biosciences Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
    (Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
    (Date:7/29/2015)... MILWAUKEE, Wis. (PRWEB) , ... July 29, 2015 ... ... facility identification solutions, today announced its GHS Label Guide . To align ... Harmonized System (GHS), this guide includes explanations of label components, an example of ...
    (Date:7/29/2015)... ... , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes ... The current system received a score of 0 (range -10 to +10) for its ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several ...
    Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
    ... Jan. 10, 2012 Saladax Biomedical, Inc., a privately ... achieve the promise of personalized medicine for new and ... six patents within the last 12 months, bringing the ... which contain broad claims in the immunoassay space.  The ...
    ... Show) – iHealth Lab Inc., the pioneering designer and ... Blood Pressure Dock and iHealth Digital Scale today announced ... immediately when users download latest version of the companion ... Scale, the free service will enable users to instantly ...
    ... Solutions Inc. (OTCBB: BLFS), a leading developer, manufacturer, and ... freeze media for cells and tissues, today announced preliminary ... 2011. Highlights include: , Sixth consecutive quarter of record ... 13% over the third quarter and 41% over the same ...
    Cached Biology Technology:Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space 2iHealth Lab Launches Personalized Web Portal to Store Your Vitals 2BioLife Solutions 2011 Revenue Up 33% 2BioLife Solutions 2011 Revenue Up 33% 3
    (Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
    (Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
    (Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
    Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
    ... genetic variant that substantially improves survival of individuals with ... disease, has been indentified by a consortium of researchers ... and Robert Brown, MD, DPhil, Chair and Professor of ... of the KIFAP3 gene variant is reported in the ...
    ... in avian conservation is underway this spring throughout the ... A legion of highly skilled volunteer ornithologists is helping ... sites for migrating birds in the southern coastal zone ... migrants. These songbirds summer in the subarctic part of ...
    ... Lyncean Technologies, Inc. has just received a Phase ... Center for Research Resources (NCRR) to develop "Differential ... produced by the Compact Light Source (CLS). ... ongoing development of the Compact Light Source and ...
    Cached Biology News:UMMS researchers isolate first 'neuroprotective' gene in patients with amyotrophic lateral sclerosis 2Conservationists seek to identify prime stopover sites for migrating birds 2Conservationists seek to identify prime stopover sites for migrating birds 3Lyncean Technologies Inc. receives $1.2 M from NCRR to develop new imaging technique 2
    ... agarose suitable for a wide range of ... to Pulsed Field Gel Electrophoresis (PFGE). Due ... limits, Multi ABgarose can effectively separate large ... in turn means reduced band diffusion, a ...
    Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
    Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
    Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
    Biology Products: